Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of three new StarBright™ Red Dyes—StarBright ...
The blood collection tubes market presents opportunities through innovation in automated systems, advanced materials, and ...
Chief Operating Officer Jon DiVincenzo stated that Bio-Rad met its revised 2024 guidance for revenue and operating margin, achieving gross margin expansion through manufacturing productivity ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of validated antibodies for rare cell and ...
HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported second-quarter net income of $317.8 million, after reporting a loss in the same period a year ...
Citi upgraded Bio-Rad Laboratories (NYSE:BIO) to buy while downgrading Hologic (NASDAQ:HOLX) to neutral and Charles River Laboratories (NYSE:CRL) to sell as part of its Q3 earnings preview on the ...
HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a year earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback